CARB-X is pleased to see the first patient dosed in SNIPR BIOME's Phase 1b clinical trial of SNIPR001, a trial co-funded by CARB-X. Read more about SNIPR001, a CRISPR-armed phage therapeutic that targets E.coli in the gut, and the trial below. #AMR #StopSuperbugs #CRISPR #phage

From product pipelines to implementation networks - global efforts to scale diagnostics are accelerating. Speakers from FIND, CARB-X, Int. Centre for Antimicrobial Resistance Solutions, and The Fleming Fund share how tools can meet local needs. #AMRDxConsortium

CARB-X executive director and #BULawProf Kevin Outterson writes that while the world may have made progress against the COVID-19 pandemic, we still face another looming, but less immediately visible, crisis: antimicrobial resistance (AMR). Read more here ➡️ spr.ly/60114PqAB

CARB-X Alliance Director Betsy Wonderly Trainor attended the Children’s Health Symposium hosted by the Wyss Institute. Wonderly Trainor spoke about CARB-X’s role in addressing neonatal sepsis during a session on transforming pediatric care through novel diagnostics.

🌍 A new global collaboration to tackle #AMR through improved diagnostics innovation and access has been launched. GARDP supports this new collaboration and co-convened the launch meeting in Ghana. It is a major step toward closing the diagnostics gap and ensuring effective

This thoughtful piece from ARMoR explores how access conditionalities can shape smarter antimicrobial R&D incentives. CARB-X requires its product developers to develop stewardship and access plans to ensure products reach patients who need them. 🔗 Read: bit.ly/3HRnupF

A recent Open Access Gov piece by Melissa Gong Mitchell of AMR IndustryAlliance highlighted the urgent need to fix the broken antibiotic R&D pipeline and the role of push incentives like CARB-X in driving early-stage R&D. 🔗 Read more: bit.ly/43ZWj3e #AMR #StopSuperbugs

CARB-X welcomes the Global Leaders Group on AMR Rolling Action Plan to support the implementation of the #UNGA79 Political Declaration on AMR, which recognizes the critical role of push incentives in addressing #AMR. 🔗 Read the Rolling Action Plan here: bit.ly/4lhXnGJ

🗞️ New interview! Learn how Centauri Therapeutics is rising to the challenge of addressing AMR with its lead program, ABX-01, a novel approach aiming to treat Gram-negative bacterial infections which is supported by CARB-X. 🔗 Read here: bit.ly/4lBSKrj

Join CARB-X Chief Scientific Officer Richard Alm, PhD at a MTPConnect panel discussing innovation in antibiotic R&D, sharing insights on translating AMR research into real-world solutions. 📆 Monday, July 14 ⏰ 12 – 2 PM ACST 🔗 Register now: bit.ly/4kWKp1x

Join CARB-X Chief Scientific Officer Richard Alm, PhD at his ASM presentation highlighting some CARB-X portfolio graduates with key learnings around effective translation of novel assets into clinical development. 📆 July 16 ⏰ 9 – 10:30 AM ACST 🔗 bit.ly/44L61bq

CARB-X is proud to join AAMRNet, Australia’s leading AMR network. Addressing AMR requires global collaboration, and CARB-X is committed to accelerating innovation through international partnerships. 🔗 Learn more about AAMRNet: bit.ly/44ztMlt

CARB-X Executive Director Kevin Outterson joined a working group convened by Center for Global Development and Market Shaping Accelerator (MSA) that aims to develop an advance market commitment for a rapid diagnostic test for neonatal sepsis in LMICs. 🔗 Read here: bit.ly/44ku4xJ

The deadline is quickly approaching for CARB-X funding partner BARDA’s RFP seeking broad-spectrum antibiotics. Review the details below. Late-stage product developers are encouraged to apply. #AMR #Antibiotics #DrugDevelopment

.pharmaphorum highlights progress made to address AMR in the nine years since the O’Neill Review was published, including CARB-X’s global efforts to accelerate early-stage antibacterial innovation and fill the gap left by big pharma. 🔗 Read here: bit.ly/4kVTFlT

In response to the serious health threat of typhoid fever, CARB-X is soliciting applications for rapid, affordable tests to diagnose patients during the acute phase of the illness. Application window: Dec. 1-12 🔗Review application criteria here: bit.ly/4dTKvDj

💼 CARB-X is hiring! Are you a collaborative, self-starter with Salesforce Administrator experience? We are hiring a SALESFORCE ADMINISTRATOR & BUSINESS ANALYST who will collaborate with internal CARB-X teams and external constituents. ➡️ Apply now! bit.ly/3YLyo5V

Read below to learn about Italy's recent commitment to its national pull incentive, solidifying its legal & procedural foundation. CARB-X is pleased to see its newest funding partner taking additional steps to support AMR innovation. Damiano de Felice 🔗: bit.ly/41lTau8